Teva agreed to buy Emalex Biosciences for $700 million upfront, aiming to bring an NDA-near Tourette syndrome candidate into its neurology pipeline. The acquisition positions the deal as Teva’s largest in about a decade, according to the reporting. The strategy hinges on Emalex’s Tourette drug, which is described as close to approval. The transaction is meant to leverage Teva’s existing neurology footprint while accelerating development and commercialization pathways. Analyst commentary framed the rationale around potential synergies with Teva’s pediatric neurology focus and the opportunity to add an NDA-ready asset in an area with limited durable, mechanism-diverse options. The move reinforces how large pharmaceutical companies continue to supplement internal discovery with late-stage biotech transactions when development timing is critical.